Clinical Trial

A Study of Azacitidine and Venetoclax Versus a Stem Cell Transplant in People 65 Years and Older With Acute Myeloid Leukemia

Withdrawn Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
Lack of funding
Summary
The researchers are doing this study to find out if an allogeneic hematopoietic stem cell transplant (HSCT) or maintenance therapy with azacitidine and venetoclax is more effective at keeping AML from coming back (relapsing).
Protocol Amendment History 4 changes
critical Withdrawn before enrolling 2026-08-06
critical Trial withdrawn: Lack of funding 2026-08-06
notable Enrollment reduced: 100 -> 0 participants 2026-08-06
notable Trial sites reduced: 7 -> 0 locations 2026-08-06
Trial Details
NCT Number NCT06903702
Lead Sponsor Memorial Sloan Kettering Cancer Center
Collaborators: Genentech, Inc.
Conditions Acute Myeloid Leukemia
Start Date 2026-08-04
Primary Completion 2027-06 (estimated)
Study Completion 2027-06 (estimated)
Updated on ClinicalTrials.gov 2026-08-05